Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
7944 patients, 1189 with VD) were included.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Doublet regimens incorporating chemotherapy or abiraterone remain viable alternatives. Further prospective studies are needed to refine treatment selection based on VD-specific biology and organ-specific metastatic patterns.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.6%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[BACKGROUND AND OBJECTIVE] Metastatic hormone-sensitive prostate cancer (mHSPC) patients with visceral disease (VD) represent a high-risk subgroup associated with poor prognosis.
- 95% CI 0.21-0.82
- HR 0.42
- 연구 설계 meta-analysis
APA
Flauto F, Neola G, et al. (2025). Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis.. European urology oncology. https://doi.org/10.1016/j.euo.2025.06.008
MLA
Flauto F, et al.. "Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis.." European urology oncology, 2025.
PMID
40645821 ↗
Abstract 한글 요약
[BACKGROUND AND OBJECTIVE] Metastatic hormone-sensitive prostate cancer (mHSPC) patients with visceral disease (VD) represent a high-risk subgroup associated with poor prognosis. Despite the introduction of treatment intensification strategies, the optimal systemic therapy for these patients remains unclear. This network meta-analysis (NMA) aims to evaluate the efficacy of the current therapeutic combinations in terms of overall survival (OS) in the subgroup of patients with VD.
[METHODS] A systematic review and NMA was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines (PROSPERO: CRD42025642120). Phase 3 randomised controlled trials assessing systemic therapies for mHSPC were identified through the PubMed, Cochrane, and Embase databases. Only studies reporting OS outcomes for patients with VD were included. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted and analysed using a frequentist NMA framework. The risk of bias was assessed using the Confidence in Network Meta-Analysis (CINeMA) tool.
[KEY FINDINGS AND LIMITATIONS] Eight phase 3 trials (7944 patients, 1189 with VD) were included. The androgen deprivation therapy (ADT) + docetaxel + darolutamide combination was the most effective regimen (HR = 0.42, 95% CI: 0.21-0.82). Among doublets, ADT + docetaxel (HR = 0.53, 95% CI: 0.30-0.93) and ADT + abiraterone (HR = 0.58, 95% CI: 0.41-0.83) showed superior efficacy to other androgen receptor pathway inhibitor-based doublet regimens, including combinations with enzalutamide, apalutamide, and darolutamide. The absence of individual patient data and the lack of efficacy data stratified by metastatic site (liver or lung involvement) were the key limitations.
[CONCLUSIONS AND CLINICAL IMPLICATIONS] Treatment intensification with triplet therapy (ADT + docetaxel + darolutamide) provides the greatest OS benefit in mHSPC patients with VD. Doublet regimens incorporating chemotherapy or abiraterone remain viable alternatives. Further prospective studies are needed to refine treatment selection based on VD-specific biology and organ-specific metastatic patterns.
[METHODS] A systematic review and NMA was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines (PROSPERO: CRD42025642120). Phase 3 randomised controlled trials assessing systemic therapies for mHSPC were identified through the PubMed, Cochrane, and Embase databases. Only studies reporting OS outcomes for patients with VD were included. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted and analysed using a frequentist NMA framework. The risk of bias was assessed using the Confidence in Network Meta-Analysis (CINeMA) tool.
[KEY FINDINGS AND LIMITATIONS] Eight phase 3 trials (7944 patients, 1189 with VD) were included. The androgen deprivation therapy (ADT) + docetaxel + darolutamide combination was the most effective regimen (HR = 0.42, 95% CI: 0.21-0.82). Among doublets, ADT + docetaxel (HR = 0.53, 95% CI: 0.30-0.93) and ADT + abiraterone (HR = 0.58, 95% CI: 0.41-0.83) showed superior efficacy to other androgen receptor pathway inhibitor-based doublet regimens, including combinations with enzalutamide, apalutamide, and darolutamide. The absence of individual patient data and the lack of efficacy data stratified by metastatic site (liver or lung involvement) were the key limitations.
[CONCLUSIONS AND CLINICAL IMPLICATIONS] Treatment intensification with triplet therapy (ADT + docetaxel + darolutamide) provides the greatest OS benefit in mHSPC patients with VD. Doublet regimens incorporating chemotherapy or abiraterone remain viable alternatives. Further prospective studies are needed to refine treatment selection based on VD-specific biology and organ-specific metastatic patterns.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Real-world Treatment Selection and Shared Decision-making in De Novo Metastatic Castration-sensitive Prostate Cancer in Japan.
- Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection-Results of the MEET-URO 22 Study.
- Characterization and validation of a bone metastatic castration-resistant prostate cancer model as a nanomedicine evaluation platform.
- Harnessing Folate-Mediated PSMA Targeting for Precision Therapy: An Intelligent Liposomal Nanoplatform Against Prostate Cancer.
- Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients.
- Health-related Quality of Life With ARPIs in mHSPC: Insights From a Network Meta-analysis.